Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's EV-to-FCF or its related term are showing as below:
SHSE:600535'
s EV-to-FCF Range Over the Past 10 Years
Min: -261.96 Med: 12.86 Max: 232.13
Current: 10.42
During the past 13 years, the highest EV-to-FCF of Tasly Pharmaceutical Group Co was 232.13. The lowest was -261.96. And the median was 12.86.
SHSE:600535's EV-to-FCF is ranked better than 77.58% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs SHSE:600535: 10.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tasly Pharmaceutical Group Co (SHSE:600535) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tasly Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Tasly Pharmaceutical Group Co's share price for today is ¥14.59.
Tasly Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.778.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tasly Pharmaceutical Group Co EV-to-FCF Related Terms
Tasly Pharmaceutical Group Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's EV-to-FCF falls into.
Tasly Pharmaceutical Group Co's current Enterprise Value is ¥20,308 Mil.
Tasly Pharmaceutical Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,978 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a EV-to-FCF of 10.27 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 20% below median its historical median of 12.86. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #126 out of 562 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is Tasly Pharmaceutical Group Co's EV-to-FCF too high?
Tasly Pharmaceutical Group Co's current EV-to-FCF of 10.27 is 20% below median its 10-year median of 12.86. The Drug Manufacturers industry median EV-to-FCF is 21.06. Tasly Pharmaceutical Group Co's value of 10.27 is 51.2% below this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #126 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #126 out of 562 companies for EV-to-FCF. This places Tasly Pharmaceutical Group Co in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 21.06. Tasly Pharmaceutical Group Co's value of 10.27 is 51.2% below this benchmark. While the company's 10-year median is 12.86 vs. the industry median of 21.06, Tasly Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current EV-to-FCF of 10.27 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current EV-to-FCF is 10.27, which is 20% below median its own 10-year median of 12.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current EV-to-FCF is 10.27, which is 20% below median its 10-year median of 12.86 and 51.2% below the Drug Manufacturers industry median of 21.06. Tasly Pharmaceutical Group Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current EV-to-FCF is 10.27 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
EV-to-FCF: 10.27 (20% below median its 10-year median of 12.86)
GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
Industry Position: 51.2% below the Drug Manufacturers median (#126 of 562)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
79GF Score
Get the complete analysis for SHSE:600535
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
